24 Hrs
Source:
الاقتصادية
Weight loss drugs across 5 nations
The article discusses the price disparities of the medications Ozempic and Mounjaro, used globally to treat obesity and diabetes. The United States ranks as the most expensive, with an average monthly cost of $1,070, which is nearly 3.8 times higher than in Saudi Arabia—the least costly among countries with official data—where the average price for both medicines is around $224. Both drugs are produced by two American companies. This pricing difference is due to Saudi Arabia’s pricing mechanism, which bases prices on a reference to 16 countries and uses a unified price across different dosages of the same medication, explaining the stability of local prices. In contrast, Europe has seen price increases: Britain raised Mounjaro's price by over 170% starting September 2025, while Japan reduced the price by 25% from August 2026, despite Ozempic’s price escalating after some dosage formulations were discontinued. Despite efforts to lower prices in the American market, the average monthly cost remains high. Data indicate that in 2026, the official prices are $1,028 for Ozempic and $1,112 for Mounjaro, with a plan to reduce Ozempic’s price to $675 starting January 2027. Separately, Saudi Arabia announced the approval of the first daily oral alternative to injections, developed by Foundo, with prices ranging between 517 and 1,229 riyals. This move aims to boost competition in the pharmaceutical market.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)